Jefferson Health

Physician Profile

Adam Dicker, MD, PhD

Jefferson University Physician

Academic Title: Professor
Chair, Department of Radiation Oncology

Specialties
Radiation Oncology
Radiation Oncology - Bladder Cancer
Radiation Oncology - Brain Tumor
Radiation Oncology - Kidney Cancer
Radiation Oncology - Prostate Cancer
Radiation Oncology - Testicular Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
Bodine Center, Suite G-301
111 South 11th Street
Philadelphia PA 19107
Phone: (215) 955-6702
Fax: (215) 955-0412

Medical Services

Years in Practice

20

Board Certifications

  • Radiation Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011,2010

Personal Statement

I provide personalized medicine using the latest developments in individualized genomic health. Each patient is treated as a family member.

Education

  • Cornell University Medical College, Medical School

Internship

  • Lenox Hill Hospital, NY

Residency

  • Memorial Sloan-Kettering Cancer Center, NY

Fellowship

  • Memorial Sloan-Kettering Cancer Center, NY

Recent Publications

Closed loop control of a robot assisted smart flexible needle for percutaneous intervention

Reply to C.G. Rusthoven et al

Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data

Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy

Radiation therapy after radical prostatectomy for prostate cancer: Evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer

American society of clinical oncology policy statement update: The critical role of phase I trials in cancer research and treatment

Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: Evaluation of outcomes in the regione Emilia-Romagna, Italy

African-American race is a predictor of seminal vesicle invasion after radical prostatectomy

Current Clinical Trials Testing Combinations of Immunotherapy and Radiation

African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men

Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes

Quantifying unnecessary normal tissue complication risks due to suboptimal planning: A secondary study of RTOG 0126

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes

A tissue biomarker -based model that identi fies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02

Adjuvant radiation for node-positive disease after prostatectomy: More good news, but who will listen?

Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound

The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness

AAPM and GEC-ESTRO guidelines for image-guided robotic brachytherapy: Report of Task Group 192